Received March 11, 2009 . Accepted January 26, 2010. Available online February 5, 2010 . Published March 12, 2010. Myocardial infarction (MI) leads to myocyte death causing progressive structural and functional changes in the heart. This cardiac remodeling contributes to abnormal left ventricle (LV) function and to the development of heart failure (1) . In most patients, pharmacological therapies are successful in slowing the development of heart failure but in some the disease progresses in spite of drug therapy and the only therapeutic option is cardiac transplantation (2) . However, the search for compatible donors and immune suppression limit the application of this procedure and alternative therapies are needed. For these reasons, cell therapy has become a novel option for patients with ischemic heart disease.
Cell transplantation has been investigated intensively in the setting of MI. Many cell types such as fetal cardiomyocytes, embryonic stem cells, skeletal myoblasts, and bone marrow stem cells have been evaluated in animal models (for a review, see Ref.
3). Skeletal myoblasts and bone marrow-derived cells have been the cell types most frequently used for the treatment of myocardial infarction because of their autologous nature, easy availability and the lack of specific ethical questions about their use in medicine. However, neither cell type is ideal for therapy. Skeletal myoblasts do not express connexin 43 (4) and may cause arrhythmias when transplanted (5 nuclear cells isolated from patients with chronic ischemic cardiomyopathy have reduced functional capacity and migratory response to stromal-derived factor 1, which can limit the regenerating potential of these cells. Furthermore, these cells have been reported to decrease in numbers and viability with age (7). On the basis of the limitations of these two cell types, the search for a more suitable cell has led investigators to study the repair potential of cord blood-derived cells in acute MI. Henning et al. (8, 9) and Wu et al. (10) reported that human umbilical cord blood (hUCB)-derived cells injected directly into the myocardium were effective in reducing infarct size and improving ventricular function in non-immunosuppressed rats. Further beneficial effects of cord blood cell therapy after acute MI in immunosuppressed animals have been reported (11) (12) (13) . Hirata et al. (11) reported that transplantation of hUCB-derived CD34 + cells significantly improved ventricular function in infarcted animals. These cells were also reported to be able to migrate to the infarcted myocardium, engrafting and participating in neoangiogenesis, and thus beneficially influencing the remodeling process (12) . Moreover, intravenous delivery of hUCB-derived CD133 + cells was reported to produce functional recovery by preventing scar thinning and LV systolic dilatation (13) . In all studies in which the mononuclear fraction of hUCB was used, the cells were obtained from cryopreserved material. When specific cell types derived from hUCB were used (mesenchymal, CD133 + , CD34 + and unrestricted somatic stem cells), fresh cord blood was the source. However, there are no reports in the literature comparing the therapeutic potential of fresh and frozen mononuclear cord blood cells. Therefore, the aim of the present study was to investigate the efficacy of fresh and cryopreserved hUCB mononuclear cells for the treatment of acute MI in nonimmunosuppressed rats subject to permanent ligation of the left coronary artery.
Material and Methods

Animals
All procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the USA National Institutes of Health (NIH Publication No. 85-23, revised 1996) as attested by the Animal Experimentation Ethics Committee of UFRJ.
Wistar rats (200-250 g) were housed at controlled temperature (23°C) with daily exposure to a 12-h light-dark cycle (lights on from 8:00 am to 8:00 pm) and free access to water and standard rat chow. The animals were divided into five groups: control rats (N = 10); sham-operated rats (N = 10); infarcted but not treated rats (INT, which received vehicle only; N = 9); infarcted rats treated with either fresh (N = 5) or cryopreserved hUCB mononuclear cells by intramyocardial injection (N = 7).
Myocardial infarction
MI was induced by left artery descendent ligation (14) . Briefly, rats were anesthetized with halothane (Merck, Germany) and a small thoracotomy was made on the left side between the 5th and 6th ribs. After exposing the heart, the descending branches of the left coronary artery were permanently occluded with a 5-0 silk suture, and the chest was closed. Sham-operated animals underwent the same procedure but without coronary ligation.
Cell preparation
hUBC samples were collected from normal human fullterm pregnancies without concomitant infectious diseases after written parental informed consent and institutional approval by the UFRJ Review Board. Fresh hUCB were collected 24 h before intramyocardial administration and maintained at 4°C. Cryopreserved hUCB samples were obtained from a cryopreservation UCB bank from cord that did not meet the minimum number of cells required for cryopreservation and would therefore be discarded. Samples were stored frozen for 1 month and then thawed at 37°C and used. The mononuclear fraction of hUCB was obtained by Ficoll gradient centrifugation (Ficoll-Paque Plus, 1077 g/mL GE Healthcare, Sweden) after extensive washing in phosphate-buffered saline (PBS) with 5% fetal bovine serum (Life Technologies ® , USA) and centrifugations at 480 g for 7 min. In some experiments the mononuclear cells were labeled with Hoechst 33342 (Sigma, USA). The cells were washed three times with PBS and the supernatant of the last wash was retrieved and incubated in vitro with cells in culture to ascertain that extruded dye would not label new cells. After isolation and Hoechst staining, cell viability was analyzed by Trypan blue exclusion and was >95%.
Cell transplantation
Three hours after coronary occlusion, animals were anesthetized and ECG and ECHO were performed to confirm infarction. The chest was immediately opened and 100 µL saline containing 1 x 10 7 mononuclear hUCB was infused into the myocardium at one or two distinct points along the border of the infarction. The infarcted non-treated animals received the same volume of PBS.
Electrocardiogram
The animals were anesthetized with ketamine and xylazine (50 and 5 mg/kg, respectively, ip). Rats were placed in the supine position and electrodes connected to surgical needles were inserted subcutaneously in order to record the classical six limb leads (L1, L2, L3, aVR, aVL, and aVF) as previously described (15) . The angle of the left ventricular depolarization vector (âQRS) and the presence of Q wave in L1 were determined from recordings obtained at 50 mm/s with a sensitivity of 20 mm/mV (Cardimax FX-2111, Fukuda Denshi, Japan). âQRS data are reported as frequency of animals with âQRS larger than 90° (right axis deviation) or between 0 and 90° (normal axis). âQRS >90° and presence of Q wave in L1 were used as evidence of infarction (15) . Parameters were evaluated 3 h after left artery descendent ligation and 3 weeks after cell or saline injection.
Echocardiogram
Echocardiographic examination was performed in a blind manner by the same echocardiographist according to American Society of Echocardiography (ASE) recommendations. We used an echocardiographic color system (Megas/Esaote, Italy) equipped with a 10-MHz electronicphased-array transducer. Short-axis two-dimensional views of the LV were taken at the level of the papillary muscles to obtain the M-mode recordings. LV end-diastolic dimensions (LVEDD), LV end-systolic dimensions (LVESD), shortening fraction [SF = (LVEDD -LVESD) / LVEDD) *100] and ejection fraction [EF = (LVEDD) 3 -(LVESD) 3 / (LVEDD) 3 *100] were measured. In order to estimate global LV function, we calculated LV diastolic and systolic area (LVDA and LVSA, respectively) to determine shortening fractional area [SFA (%) = (LVDA -LVSA) / LVDA *100]. Additionally, the total and the akinetic perimeters of the LV in systole (LVTP and LVAP, respectively) were determined in order to calculate percent LV akinesis [%LVA = (LVAP / LVTP) *100] at the level of the papillary muscles.
Cardiopulmonary test
Three weeks after the surgical procedure, animals were weighed and their cardiac function was analyzed under physiological stress (exercise). The test was performed according to an established protocol (16) . We evaluated the maximal duration of running endurance by the animals and their maximal oxygen consumption (VO 2 max). In brief, after an adaptation period of 3 days, the animals started to run in a treadmill with a constant slope of 10° at a velocity of 17 cm/s. The velocity was increased every 2 min by 2 cm/s until exhaustion. Stainless steel grids provided an electrical shock to keep the animals running. Exhaustion was determined whenever the animal stayed on the steel grids for more than 1 min despite the shocks.
Left ventricular pressure measurements in unanesthetized rats
One day after the cardiopulmonary test, animals were anesthetized with ketamine/xylazine as described above, and the right carotid artery was cannulated with a PE10 catheter. One extremity of the catheter was inserted into the left ventricle and the opposite end was tunneled back and exposed between the scapulae. With the animal free to walk about in its cage 24 h after this procedure, the catheter was connected to a pressure transducer (MLT0380/D, ADInstruments, Australia) coupled to a Power Lab400 acquisition system (ADInstruments). After an adaptation period of 30 min, LV pressure acquisition was started. The LV parameters evaluated were: LV end-diastolic pressure (LVEDP), LV end-systolic pressure (LVESP), LV developed pressure [(LVDP) = LVESP -LVEDP], cardiac index of LV contractility (dP/dT+), and index of LV relaxation (dP/ dT-). All data were measured using the Chart 4 software (PowerLab, ADInstruments).
Histological procedures
The animals were sacrificed following the LV pressure measurements. The hearts were excised, fixed with 4% paraformaldehyde and cut into three consecutive sections from base to apex of the LV: sections A, B, and C, respectively. Section B contains the major portion of the LV infarcted region, in which the walls are macroscopically very thin. Samples from these regions were embedded in OCT (Tissue Tek), frozen at -80°C and cut into 5-µm thick sections. The sections were analyzed with an epifluorescence microscope (Axiovert 100, Carl Zeiss, Germany) to evaluate the presence of cells labeled with Hoechst 33342 (Sigma).
Statistical analysis
Data are reported as means ± SD. Comparisons between two groups were made by the Student t-test. Differences between more than two groups were compared by oneway analysis of variance. Differences were considered to be significant when P < 0.05 after Bonferroni's correction.
Results
Electrocardiographic analysis
Three weeks after cell therapy, electrocardiographic parameters in the groups treated with fresh and cryopreserved hUCB cells were typical of infarcted animals. In other words, the Q wave was present in L1 and âQRS was >90° (Table 1 ). In contrast, in control and sham animals Q wave was always absent in L1 and âQRS was <90°. ECGs recorded 3 h after infarction surgery or 3 weeks after cell therapy were not significantly different between saline-and the two hUCB-treated groups. No significant difference in measured ECG parameters was observed between the two groups treated with fresh or cryopreserved hUCB.
Echocardiographic analysis
The two-dimension echocardiographic images taken at the level of the papillary muscle 3 h after infarction showed that the percentage of LV akinesis was 43.4 ± 6.0% (INT); 47.10 ± 9.2% (cryopreserved hUCB); 43.71 ± 2.8% (fresh hUCB). These infarction sizes were not statistically different.
After 3 weeks, LVEDD and LVESD of the infarcted groups were significantly greater than those of the sham group (P < 0.001). In cryopreserved hUCB, LVEDD and LVESD were 8.9 ± 0.60 and 6.10 ± 0.24 mm, respectively, while in fresh hUCB these parameters were 10.0 ± 0. (LVEDD) and 8.9 ± 0.60 mm (LVESD). Moreover, these parameters were significantly greater in both hUCB groups than in the INT group (P < 0.05; Table 2 ). The ejection fraction was equally reduced in both infarcted groups treated with hUCB (cryopreserved hUCB = 48.60 ± 10.47 and fresh hUCB = 38.0 ± 11.5%) and both were significantly reduced in comparison with sham rats (89.50 ± 10.89%). This same pattern was observed in SF% and SFA%. In both groups treated with hUCB, SF% was about 20%. Again, no statistical difference in echocardiographic parameters was found between the fresh and cryopreserved hUCB groups.
Furthermore, echocardiographic parameters before and after hUCB treatment were not statistically different for both treatments.
Left ventricular pressure measurements in unanesthetized rats LV pressure was measured in unanesthetized rats only 3 weeks after the surgical procedure. No statistical differences in LV pressure measurements (dP/dT+, dP/ dT-, and LVDP) were observed between INT and the two hUCB-treated groups, as shown in Table 3 . However, all Table 1 . Electrocardiographic parameters of control, sham-operated and infarcted rats 3 weeks after the surgical procedure. 
Cardiopulmonary exercise testing
As shown in Figure 1 , the total exercise time and VO 2 max of the infarcted groups (INT and cryopreserved hUCB) were smaller when compared to sham animals. These parameters were not significantly different between cryopreserved hUCB-treated group and the untreated infarcted group.
Microscopic analysis
Histologic sections revealed the presence of Hoechststained nuclei in the left ventricle of fresh and cryopreserved hUCB-treated animals 3 weeks after cell injection (Figure 2 ). These cells were found mainly in section B (see Histological procedures) at the border of the infarcted region and are mononuclear cells that were labeled before injection.
Discussion
Cell-based therapies have been proposed as an alternative treatment for many cardiovascular diseases. Bone marrow-derived cells from patients have been used in clinical trials to improve cardiac function in patients with acute MI and chronic ischemic heart disease (for a review, see Ref. 17) . However, the number and biological activity of mononuclear cells isolated from the bone marrow of older people or from patients with ischemic cardiomyopathy are significantly reduced (7) . Based on these findings, several groups have investigated the application of hUCB in acute MI models (7, 8, (10) (11) (12) (13) .
In most of these studies, human cells have been injected into genetically immune incompetent animals or into pharmacologically immunosuppressed ones. However, even when using human cells in immunocompromised animals, results have been contradictory. At present, no more than fifteen original studies have used hUCB cells in models of MI. Given the importance that hUCB cells may have for therapeutic purposes and the contradictory results, the experiments reported here are relevant to the field, especially because, to our knowledge, we are the first to compare freshly isolated and cryopreserved mononuclear cells.
In infarcted NOD/SCID mice, CD34 + cells from hUCB have been shown to promote angiogenesis (12, 18) while mononuclear cells had no effect (18) . In immunosuppressed rats, CD34 + and CD133 + cells from hUCB have been reported to improve LV function after acute MI (11, 13) .
Henning et al. (8) used immunocompetent rats without immune suppression and reported reduction in infarct size and improvement in ventricular function after hUCB mononuclear cell injection (7, 8) . Similar results have been reported by Wu et al. (10) using mesenchymal stem cells from hUCB in infarcted rat models without immune suppression. This result is astonishing from the immunological point of view and may indicate that the use of allogeneic cord blood could be a therapeutic alternative for cardiac patients, rendering hUCB even more attractive for clinical use. Unfortunately our results do not confirm these findings. We have analyzed possible differences in the experimental models. First, since we tested freshly isolated and cryopreserved cells, differences in cell handling cannot explain the different results obtained. The number of cells injected also does not seem to justify the discrepancy in results; we injected more cells than most other groups. Henning et al. (8) have reported a dose-dependent effect of intramyocardially injected hUCB cells in their rat model, with the highest dose used (4 x 10 6 cells) being the most effective. Cell processing differences are unlikely to account for the differences in results, and since the only functional test to which cells were subjected after processing was exactly their effect in the infarction model (as opposed to colony forming or migration assays), and cell viability after processing was similar in most studies, it is difficult to attribute to cell processing the different results without additional comparisons of functional capabilities. The content of CD34 + cells in the mononuclear fraction was similar in all models, ranging from 1 to 3%. One possible difference is that in our model we determined echocardiographic parameters immediately after infarction, guaranteeing that all infarcted animals started out from the same baseline value and thus validating comparisons after cell or placebo injection.
The results obtained from experimental models using larger animals have also been contradictory. While Kim et al. (19) reported improvement in ventricular function after intramyocardial hUCB cell injection in immunosuppressed infarcted pigs, Moelker et al. (20) found no evidence for cardiac improvement in the same animal model, using the same cell type but using the intracoronary injection route.
In conclusion, the mononuclear fraction of cord blood is not a suitable source for xenogenic cardiac cell therapy in non-immunosuppressed animals.
